ADCsessions in oncology 2022

Overview of the recent results and currentresearch of Antibody-Drug Conjugatesacross cancer types: breast, lung, gastrointestinal and genitourinary


Dr. Eva Ciruelos(University Hospital 12 de Octubre (Madrid), HM Hospitales and Vice President of SOLTI)

Dr. Mafalda Oliveira (Vall d’Hebron Institute of Oncology (Barcelona) and SOLTI Governing Board Member)

16:00 – Welcome by coordinators

16:10 – Overview – ADCs in cancer
Speaker: Dr. Barbara Pistilli (Institut de Cancérologie Gustave Roussy, Paris)
Discussants: coordinators, Dr. Gail D. Lewis (Genentech, Roche, virtually)

16:45 – Target-based discussion tables

Novel TROP-2 approaches in cancer
Speaker: Dr. Aditya Bardia (Massachusetts General Hospital, virtual lecture)
Discussants: Dr. Ignacio Durán (Hospital Universitario Marqués de Valdecilla), Dr. Daejin Abidoye (Gilead), Dr. Gilles Gallant (Daiichi-Sankyo)

Strategies to overcome resistance in HER2 positive tumors
Speaker: Dr. Javier Cortés (International Breast Cancer Center)
Discussants: Dr. Enriqueta Felip (Vall d’Hebron Institute of Oncology, Barcelona), Dr. Andrés Cervantes (University Clinical Hospital of Valencia, virtual), Dr. Zeeshan Rasheed (AstraZeneca)

HER3 as a new biomarker in cancer
Speaker: Dr. Egbert Smit (Leids Universitair Medisch Centrum, Leiden, Netherlands, virtual lecture)
Discussants: Dr. Luis Paz-Ares (University Hospital 12 de Octubre, Madrid), Dr. Juan Miguel Cejalvo (University Clinical Hospital of Valencia), Dr. Gilles Gallant (Daiichi-Sankyo)

Other targets and drugs: nectin 4 and more
Speaker: Dr. Funda Meric-Bernstam (MD Anderson Cancer Center, virtual lecture)
Discussants: Dr. Daniel Castellano (University Hospital 12 de Octubre, Madrid), Dr. Emiliano Calvo (Centro Integral Oncológico Clara Campal), Dr. Valentina Boni (Quirónsalud, Madrid)

19:20 – Conclusions and closure

The event is finished.


Mar 22 2022


16:00 - 19:20

Next Event

QR Code

Comments are closed.